Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Kairos Pharma Analyst Ratings and Price Targets | AMEX:KAPA | Benzinga
Kairos Pharma Ltd has a consensus price target of $9 based on the ratings of 2 analysts. The high is $9 issued by D. Boral Capital on March 20, 2025. The low is $9 issued by D. Boral Capital on March 20, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital on March 20, 2025, February 26, 2025, and February 18, 2025, respectively. With an average price target of $9 between D. Boral Capital, there's an implied 848.37% upside for Kairos Pharma Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Kairos Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 848.37% | D. Boral Capital | Jason Kolbert47% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 848.37% | D. Boral Capital | Jason Kolbert47% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | 848.37% | D. Boral Capital | Jason Kolbert47% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 848.37% | D. Boral Capital | Jason Kolbert47% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/22/2025 | Buy Now | 848.37% | D. Boral Capital | Jason Kolbert47% | $9 → $9 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 848.37% | D. Boral Capital | Jason Kolbert47% | $9 → $9 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | 848.37% | EF Hutton | Jason Kolbert47% | → $9 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Kairos Pharma (KAPA) stock?
The latest price target for Kairos Pharma (AMEX:KAPA) was reported by D. Boral Capital on March 20, 2025. The analyst firm set a price target for $9.00 expecting KAPA to rise to within 12 months (a possible 848.37% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kairos Pharma (KAPA)?
The latest analyst rating for Kairos Pharma (AMEX:KAPA) was provided by D. Boral Capital, and Kairos Pharma maintained their buy rating.
When was the last upgrade for Kairos Pharma (KAPA)?
There is no last upgrade for Kairos Pharma
When was the last downgrade for Kairos Pharma (KAPA)?
There is no last downgrade for Kairos Pharma.
When is the next analyst rating going to be posted or updated for Kairos Pharma (KAPA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kairos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kairos Pharma was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Kairos Pharma (KAPA) correct?
While ratings are subjective and will change, the latest Kairos Pharma (KAPA) rating was a maintained with a price target of $9.00 to $9.00. The current price Kairos Pharma (KAPA) is trading at is $0.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.